Leukemia & Lymphoma最新文献_第3页

CAR-T cell-associated neurotoxicity during therapy of hematologic malignancies: incidence, clinical features, predictive biomarkers and management measures. 恶性血液病治疗期间CAR-T细胞相关的神经毒性：发病率、临床特征、预测性生物标志物和管理措施

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-11 DOI: 10.1080/10428194.2025.2502810

R Velasco, I Abad-Inchaurrondo, A Sureda

{"title":"CAR-T cell-associated neurotoxicity during therapy of hematologic malignancies: incidence, clinical features, predictive biomarkers and management measures.","authors":"R Velasco, I Abad-Inchaurrondo, A Sureda","doi":"10.1080/10428194.2025.2502810","DOIUrl":"https://doi.org/10.1080/10428194.2025.2502810","url":null,"abstract":"Chimeric antigen receptor T-cell therapy (CAR-T cell therapy)-associated neurotoxicity includes a range of neurological side effects following CAR-T cell infusion. While ICANS is already a well-recognized, widely described neurological complication, the spectrum of neurological toxicities associated with CAR-T cell therapy has widened to include other, less common but emerging neurotoxicity syndromes. These have been observed with its broader use and the development of new agents. Movement and neurocognitive toxicity represent a recently described and challenging syndrome associated with BCMA-directed CAR-T cell therapies. Cranial and peripheral neuropathies, as well as myelopathy have increasingly been identified. Rare forms of cerebellar toxicity have been described with under development agents as well. Furthermore, strokes or tumor inflammation-associated syndrome (TIAN) in patients with CNS disease may elicit an emergency consultation. Finally, classical forms of acute toxic leukoencephalopathy have been described in a few patients receiving fludarabine as lymphodepleting treatment before CAR-T cell infusion. These forms of neurotoxicity vary in severity, with some cases being severe and even life-threatening in the context of CAR-T cell therapy. The present review summarizes several types of neurotoxicity associated with CAR-T cell therapy in patients with hematologic malignancies, focusing on available data on incidence, clinical presentation, prediction, diagnostics and therapeutic management.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progression of disease within 6 months: revised early disease progression threshold for ENKTL. 6个月内疾病进展：修订ENKTL的早期疾病进展阈值。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-11 DOI: 10.1080/10428194.2025.2516257

Miao Zhong, Hailing Liu, Renfu Gui, Jing Zhang, Sanmei Wang, Yi Miao, Chongyang Ding, Lvwen Chen, Yuxiao Zhao, Xiran Wang, Xiaoyan Qu, Zhengxu Sun, Ran Li, Jianyong Li, Lei Cao, Lei Fan

{"title":"Progression of disease within 6 months: revised early disease progression threshold for ENKTL.","authors":"Miao Zhong, Hailing Liu, Renfu Gui, Jing Zhang, Sanmei Wang, Yi Miao, Chongyang Ding, Lvwen Chen, Yuxiao Zhao, Xiran Wang, Xiaoyan Qu, Zhengxu Sun, Ran Li, Jianyong Li, Lei Cao, Lei Fan","doi":"10.1080/10428194.2025.2516257","DOIUrl":"https://doi.org/10.1080/10428194.2025.2516257","url":null,"abstract":"The progression of disease (POD) within 24 months is well-established as an early indicator in various lymphomas. However, the aggressive nature of extranodal NK/T-cell lymphoma (ENKTL) necessitates a shorter assessment period. In this study, we examined POD metrics in 170 newly diagnosed ENKTL patients receiving asparaginase-based regimens. Patients were divided into three groups based on relapse/progression timing: aggressive group (POD6), progressive group (POD6-24), and stable group (POD > 24). The median overall survival (OS) in the POD6 group was 16.5 months, while the median OS was not reached in the remaining two groups. Survival outcomes were comparable between the populations with POD6 and POD24. Cox regression analysis identified POD6 as an independent risk factor for OS, regardless of traditional risk stratification. In conclusion, POD6 is a valuable early prognostic marker for ENKTL, serving as a long-term prognosis surrogate for clinical studies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation. 氟达拉滨剂量对造血干细胞移植移植相关结果的影响。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-11 DOI: 10.1080/10428194.2025.2509701

Ana Maria Meireles, Ana Carolina Dominguesde Oliveira Rodrigues Amarante, Beatriz Mota Coelho Marques Catita, Maria Teresa Pegado Barroso Abilheira Monjardino, Pedro Martinho Gonçalves de Abreu Gouveia, Cláudia Sílvia da Rocha Moreira, Luís Cláudiode Jesus Leite, Rita Coutinho, Rosa Branca Santos Ferreira, Gil Paiva Brás, Manuel Guerreiro, Carlos Pinho Vaz, José Mário Mariz

引用次数: 0

Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor. 通过分析慢性淋巴细胞白血病的b细胞受体来了解其发病机制和生物学。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-10 DOI: 10.1080/10428194.2025.2513005

Maria Dampmann, Bastian von Tresckow, Hans Christian Reinhardt, Ralf Küppers, Julia von Tresckow

引用次数: 0

Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma. mosunetuzumab和CAR-T细胞治疗复发/难治性滤泡性淋巴瘤的成本效益

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-09 DOI: 10.1080/10428194.2025.2506498

Meng-Hsuan Lin, Jonathan Weiss, Tycel J Phillips, Dahlia Sano, Shannon A Carty, Ryan Wilcox, Monalisa Ghosh, Iman Ahmed, Victoria R Nachar, David Hutton, Yasmin H Karimi

引用次数: 0

Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models. 在小鼠模型中，吸烟与骨髓增生异常综合征和造血改变的预后不良相关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-09 DOI: 10.1080/10428194.2025.2513675

Tanya Verma, Srabani Sahu, Kith Pradhan, Ritesh Aggarwal, Shanisha Gordon-Mitchell, Sakshi Jasra, Seyedeh Shareh Dehghani, Hui Zhang, Mason Spodek, Ioannis Mantzaris, Marina Konopleva, Mendel Goldfinger, Amit Verma, Dean Hosgood, Divij Verma, Aditi Shastri, Yiyu Zou

引用次数: 0

Not just amyloidosis: the spectrum of Waldenstrom's macroglobulinemia-associated renal disease. 不仅仅是淀粉样变性：瓦尔登斯特罗姆氏大球蛋白血症相关性肾病的频谱。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-09 DOI: 10.1080/10428194.2025.2512392

Roberta Giachetti, Francesca Ravaglia, Chiara Somma, Claudia Mannucci, Francesco Scaramuzzino, Martina Rousseau, Silvia Birtolo

{"title":"Not just amyloidosis: the spectrum of Waldenstrom's macroglobulinemia-associated renal disease.","authors":"Roberta Giachetti, Francesca Ravaglia, Chiara Somma, Claudia Mannucci, Francesco Scaramuzzino, Martina Rousseau, Silvia Birtolo","doi":"10.1080/10428194.2025.2512392","DOIUrl":"https://doi.org/10.1080/10428194.2025.2512392","url":null,"abstract":"Renal involvement in Waldenström's macroglobulinemia (WM) is a rare but clinically significant complication that is often underrecognized and inadequately described in the scientific literature. When kidney damage occurs, it negatively impacts both patient prognosis and renal outcomes, highlighting the importance of early recognition and targeted therapy. While B-cell directed treatment is crucial, therapeutic strategies remain non-standardized, and much of the existing literature predates the widespread use of Bruton's tyrosine kinase (BTK) inhibitors. In this manuscript, we present a case of WM-associated heavy and light chain deposition disease successfully treated with the second-generation BTK inhibitor zanubrutinib, emphasizing the potential role of novel targeted agents in this setting. Additionally, we provide a brief review of renal complications associated with WM and discuss some therapeutic considerations. However, the available data are heterogeneous and insufficient to draw definitive conclusions regarding the relationship between clinical outcomes and specific treatment strategies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia. b细胞急性淋巴细胞白血病单克隆抗体的研究进展。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-02 DOI: 10.1080/10428194.2025.2507198

Hamideh Kamalloo, Mahnaz Fathi, Sobhan Bavandi, Fereshteh Asadi, Sheida Janati, Kumars Amini

{"title":"Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia.","authors":"Hamideh Kamalloo, Mahnaz Fathi, Sobhan Bavandi, Fereshteh Asadi, Sheida Janati, Kumars Amini","doi":"10.1080/10428194.2025.2507198","DOIUrl":"https://doi.org/10.1080/10428194.2025.2507198","url":null,"abstract":"Monoclonal antibody (mAb)-based therapies targeting CD19, CD20, and CD22 have revolutionized B-ALL treatment, offering precision and reduced systemic toxicity by engaging immune mechanisms to eliminate leukemic cells. This review synthesizes literature from PubMed, Web of Science, and ClinicalTrials.gov (2000-2024), focusing on clinical outcomes and resistance mechanisms. Bispecific T-cell engagers (e.g. blinatumomab) and CD22-directed antibody-drug conjugates (e.g. inotuzumab ozogamicin) demonstrate robust efficacy in relapsed/refractory disease. Advances in antibody engineering, such as Fc optimization, nanobodies, and humanization, enhance tumor targeting and therapeutic safety. Persistent challenges include antigen escape, stromal-mediated resistance, and treatment-related toxicities. Combinatorial approaches integrating mAbs with CAR-T cells or checkpoint inhibitors show promise in overcoming resistance pathways. Emerging technologies like artificial intelligence and deep learning are transforming antibody design by predicting epitope binding, enabling de novo protein engineering, and streamlining affinity maturation. These innovations accelerate the development of next-generation therapies, underscoring the evolving potential of precision immunotherapy of B-ALL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML). 急性髓性白血病（AML）患者诱导治疗后白细胞动力学对预后的影响。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-02 DOI: 10.1080/10428194.2025.2512029

Jesamine Jany, Jan-Henrik Mikesch, Klaus Wethmar, David Baden, Irina Osiaevi, Georg Lenz, Christoph Schliemann, Alexander Pohlmann

{"title":"Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).","authors":"Jesamine Jany, Jan-Henrik Mikesch, Klaus Wethmar, David Baden, Irina Osiaevi, Georg Lenz, Christoph Schliemann, Alexander Pohlmann","doi":"10.1080/10428194.2025.2512029","DOIUrl":"https://doi.org/10.1080/10428194.2025.2512029","url":null,"abstract":"Acute myeloid leukemia (AML) is associated with broadly varying white blood cell (WBC) counts at the time of diagnosis and treatment. This study examined the association of WBC kinetics and outcome in 443 patients of '7 + 3' intensively treated AML patients, differentiating between leukocytosis and non-leukocytosis. WBC kinetics like WBC nadir, area under the curve (AUC) and negative slope were assessed by regression analyses adjusted for known risk factors. Leukocytosis was associated with inferior overall survival (OS: HR 0.73; 95% CI 0.569-0.938; p = 0.013), event-free survival (EFS: HR 0.777; 95% CI 0.625-0.966); p = 0.013) and increased early death (ED: p < 0.001) compared to the non-leukocytosis cohort. In patients with leukocytosis - regression analyses identified higher WBC nadir and higher AUC as predictors of worse outcome (WBC: HR 1.176; 95% CI 1.03-1.342; p = 0.017 and AUC: HR 1.001; 95% CI 1-1.003; p = 0.039). In contrary, non-leukocytosis patients presented an even shorter OS the lower their WBC nadir (HR 0.298; 95% CI 0.118-0.751; p = 0.01) and AUC dropped during induction (HR 0.981; 95% CI 0.962-0.999; p = 0.041). Multivariate analyses largely confirmed these effects.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pilot study of lower doses of ibrutinib: patient body weight does not correlate with plasma ibrutinib levels during therapy. 低剂量伊鲁替尼的初步研究：患者体重与治疗期间血浆伊鲁替尼水平无关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-08 DOI: 10.1080/10428194.2025.2461672

Lisa S Chen, Prithviraj Bose, Wei Qiao, Yongying Jiang, Qi Wu, Nichole D Cruz, Michael J Keating, Varsha Gandhi

引用次数: 0